ANIK Anika Therapeutics Inc.

Anika to Issue First Quarter 2025 Financial Results on Friday, May 9, 2025

Anika to Issue First Quarter 2025 Financial Results on Friday, May 9, 2025

BEDFORD, Mass., April 25, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its first quarter 2025 financial results before the opening of the market on Friday, May 9, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights.

The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 63463. A live audio webcast and accompanying presentation materials will be available in the section of Anika's website, . The call will be archived and accessible on the same website shortly after its conclusion.

About Anika

 (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people around the world. Our focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management and Regenerative Solutions, and our products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit 

ANIKA, ANIKA THERAPEUTICS and the Anika logo are trademarks of Anika Therapeutics, Inc. or its subsidiaries or are licensed to Anika Therapeutics, Inc. for its use.

For Investor Inquiries:

Anika Therapeutics, Inc.

Matt Hall, 781-457-9554

Director, Corporate Development and Investor Relations



EN
25/04/2025

Underlying

ANIKAnika Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Anika Therapeutics Inc.

 PRESS RELEASE
Free
ANIK Anika Therapeut...

Anika to Issue First Quarter 2025 Financial Results on Friday, May 9, ...

Anika to Issue First Quarter 2025 Financial Results on Friday, May 9, 2025 BEDFORD, Mass., April 25, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its first quarter 2025 financial results before the opening of the market on Friday, May 9, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID numb...

5h / 16m 1 EN
 PRESS RELEASE
Free
ANIK Anika Therapeut...

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BEDFORD, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global leader in the Osteoarthritis (“OA”) Pain Management and Regenerative Solutions space focused on early intervention orthopedics, today announced that on April 1, 2025, Anika granted non-statutory stock options (“Options”) covering an aggregate of 3,800 shares of common stock at a per share exercise price of $15.03, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to one newly ...

April 7, 2025 1 EN
 PRESS RELEASE
Free
ANIK Anika Therapeut...

Anika Reports Fourth Quarter and Full Year 2024 Financial Results

Anika Reports Fourth Quarter and Full Year 2024 Financial Results Full Year 2024 results in line with guidance with Commercial Channel revenue up 17% Strong International OA Pain Management and greater than 40% sequential growth of Integrity™ Implant System drive Commercial Channel growth and 2024 results Key Regulatory and Clinical milestones achieved for Hyalofast®, Cingal®, and Integrity Strategic Sale of Parcus Medical complete; resources refocused on programs positioned to generate significantly higher returns BEDFORD, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Ani...

March 12, 2025 1 EN
 PRESS RELEASE
Free
ANIK Anika Therapeut...

Anika Completes Divestiture of Parcus Medical

Anika Completes Divestiture of Parcus Medical Execution of Previously Announced Plan Sharpens Focus on Hyaluronic Acid-Driven OA Pain Management and High Growth Regenerative Solutions Portfolio BEDFORD, Mass., March 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global leader in the Osteoarthritis Pain Management and Regenerative Solutions space focused on early intervention orthopedics, today announced the completion of the previously announced planned divestiture of its Parcus Medical business. Management Commentary“The sale of Parcus marks a critical step forward as we achieve the ...

March 7, 2025 1 EN
 PRESS RELEASE
Free
ANIK Anika Therapeut...

Anika to Issue Fourth Quarter and Year-End 2024 Financial Results on W...

Anika to Issue Fourth Quarter and Year-End 2024 Financial Results on Wednesday, March 12, 2025 BEDFORD, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its fourth quarter and year-end 2024 financial results after the close of the market on Wednesday, March 12, 2025 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) ...

February 26, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch